| AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity S Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ... Cancer cell 19 (1), 58-71, 2011 | 1058 | 2011 |
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations V Serra, B Markman, M Scaltriti, PJA Eichhorn, V Valero, M Guzman, ... Cancer research 68 (19), 8022-8030, 2008 | 921 | 2008 |
| Development of PI3K inhibitors: lessons learned from early clinical trials J Rodon, R Dienstmann, V Serra, J Tabernero Nature reviews Clinical oncology 10 (3), 143-153, 2013 | 854 | 2013 |
| Interrogating open issues in cancer precision medicine with patient-derived xenografts AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ... Nature Reviews Cancer 17 (4), 254-268, 2017 | 648 | 2017 |
| Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor–positive breast cancer MT Herrera-Abreu, M Palafox, U Asghar, MA Rivas, RJ Cutts, ... Cancer research 76 (8), 2301-2313, 2016 | 640 | 2016 |
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ... Oncogene 30 (22), 2547-2557, 2011 | 598 | 2011 |
| PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition YH Ibrahim, C García-García, V Serra, L He, K Torres-Lockhart, A Prat, ... Cancer discovery 2 (11), 1036-1047, 2012 | 592 | 2012 |
| Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 PJA Eichhorn, M Gili, M Scaltriti, V Serra, M Guzman, W Nijkamp, ... Cancer research 68 (22), 9221-9230, 2008 | 585 | 2008 |
| A decade of clinical development of PARP inhibitors in perspective J Mateo, CJ Lord, V Serra, A Tutt, J Balmaña, M Castroviejo-Bermejo, ... Annals of Oncology 30 (9), 1437-1447, 2019 | 518 | 2019 |
| Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors R Dienstmann, J Rodon, V Serra, J Tabernero Molecular cancer therapeutics 13 (5), 1021-1031, 2014 | 518 | 2014 |
| A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds A Bruna, OM Rueda, W Greenwood, AS Batra, M Callari, RN Batra, ... Cell 167 (1), 260-274. e22, 2016 | 442 | 2016 |
| Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor? T Von Zglinicki, V Serra, M Lorenz, G Saretzki, R Lenzen-Groβimlighaus, ... Laboratory investigation 80 (11), 1739-1747, 2000 | 377 | 2000 |
| Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ... Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011 | 372 | 2011 |
| Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells H Dev, TWW Chiang, C Lescale, I de Krijger, AG Martin, D Pilger, ... Nature cell biology 20 (8), 954-965, 2018 | 351 | 2018 |
| PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ... Science translational medicine 7 (283), 283ra51-283ra51, 2015 | 341 | 2015 |
| RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, ... Annals of Oncology 29 (5), 1203-1210, 2018 | 334 | 2018 |
| Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening V Serra, T Von Zglinicki, M Lorenz, G Saretzki Journal of Biological Chemistry 278 (9), 6824-6830, 2003 | 334 | 2003 |
| mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer M Elkabets, S Vora, D Juric, N Morse, M Mino-Kenudson, T Muranen, ... Science translational medicine 5 (196), 196ra99-196ra99, 2013 | 312 | 2013 |
| ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer RE Miller, A Leary, CL Scott, V Serra, CJ Lord, D Bowtell, DK Chang, ... Annals of Oncology 31 (12), 1606-1622, 2020 | 286 | 2020 |
| CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer SF Johnson, C Cruz, AK Greifenberg, S Dust, DG Stover, D Chi, ... Cell reports 17 (9), 2367-2381, 2016 | 262 | 2016 |
Neal RosenProfessor of Pharmacology, Memorial Sloan-Kettering Cancer CenterVerified email at mskcc.org
